Core Viewpoint - The China Securities Regulatory Commission (CSRC) has issued supplementary material requirements for BlissBio Inc. regarding its overseas listing application, focusing on operational management and financial details [1][2]. Group 1: Regulatory Requirements - CSRC has requested BlissBio Inc. to clarify the actual operation of its management and the significant influence on the management team [1]. - Specific inquiries include the pricing basis and tax implications related to the acquisition of CCCBio, as well as the tax situation during the capital reduction process in Hangzhou [1][2]. - The CSRC also seeks explanations regarding the reasons for not recognizing certain individuals as joint actual controllers and the rationale behind the stock incentive plans [2]. Group 2: Company Overview - BlissBio Inc. is a clinical-stage biopharmaceutical company focused on developing next-generation antibody-drug conjugates (ADCs) to address unmet needs in cancer treatment [2]. - The company's core product, BB-1701, targets HER2 and is aimed at treating breast cancer, non-small cell lung cancer, and other HER2-expressing cancers [2]. Group 3: Financial Performance - For the fiscal years 2023 and 2024, BlissBio Inc. reported revenues of approximately 180 million RMB and 22.59 million RMB, respectively [3]. - The company incurred losses of about 206 million RMB and 55.7 million RMB for the same periods [3].
百力司康拟港股上市 中国证监会要求补充说明公司经营管理的实际运作等情况
Zhi Tong Cai Jing·2025-10-31 13:50